Neuren Pharmaceuticals Limited

Analyst consensus places a 12-month price target of AU$23.45–AU$24.51, implying significant upside of ~40–70% from recent trading prices. Revenue forecasts have been substantially upgraded to AU$115m for 2026, representing 78% growth — well above both historical rates and the broader industry forecast of 37% annual growth.

Neuren trades at a P/E of 57.4x–73.3x, far above the global pharmaceuticals average of 20.6x and the peer average of ~29x. Morningstar flags the stock as trading at a 195% premium to its fair value estimate, suggesting the current price already embeds an optimistic scenario with little margin for error.

The CHMP's positive opinion recommending EU marketing authorisation for DAYBU® (trofinetide) opens a major new commercial market. Neuren stands to receive US$35 million upon first European commercial sale, plus tiered royalties and up to US$170 million in additional sales-based milestone payments — meaningfully diversifying its royalty income beyond the US.

Neuren's financial model is heavily reliant on royalty income from a single partner, Acadia Pharmaceuticals, for DAYBUE sales. This concentrated dependency exposes Neuren to risks outside its direct control, including Acadia's commercial execution, pricing pressures, and competitive threats in the Rett syndrome market.

Analysts have materially upgraded revenue and earnings forecasts for 2026, citing an improving sales pipeline. The company is described as having exceptional growth potential with a flawless balance sheet, and its growth rate is forecast to meaningfully outpace both its own historical trajectory and industry peers through 2028.

Neuren faces meaningful regulatory risk around NNZ-2591 and additional pipeline indications. Analyst price targets carry a high dispersion of ~17%, with targets ranging from AU$18.40 to AU$29.00, reflecting deep uncertainty about whether pipeline assets will successfully navigate clinical and regulatory hurdles to generate material future revenues.